By Staff, The Cape Breton Post
Stirling Products Limited of Australia acquired the North Sydney plant in March 2010 as a result of the bankruptcy of the former Keata plant.
Stirling Pharma plant in the Northside Business Park — File Photo
[NORTH SYDNEY, NS] — The receiver for the assets of Stirling Pharma Inc. says the Northside Business Park manufacturing plant is up for sale.
In a press release, MacKenzie, Gillis, MacDougall Inc. president Greg MacKenzie, in collaboration with PRPR Proactive Products Inc., said the tender closes Nov. 10, at 11 a.m. AST.
According to the release, the 46,000 sq. ft. GMP pharmaceutical facility is a state-of-the-art pharmaceutical manufacturing facility with the unique capability to assist clients to bring their products from the laboratory to the market by providing development, scale-up and commercial production expertise.
The facility includes pilot laboratories for formulation development, rooms with various capabilities such as high shear mixing, container blending and equipment for modified release technology. The facility also provides formulation development and testing services to manufacture and package products in solid and liquid dosage forms.
“With current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, five million bottles and blend up to 1.5 million kg of product,” said Wayne Miller, president of PRPR Proactive Products Inc. “With a fully licensed pharmaceutical plant, skilled work force and strategic geographic location, this opportunity sets the stage for significant growth for a company with a viable business plan.”
Stirling Products Limited of Australia acquired the plant in March 2010 as a result of the bankruptcy of the former Keata plant.